






Samuel B. Graitcer, Larisa Gubareva, 
Laurie Kamimoto, Saumil Doshi, 
Meredith Vandermeer, Janice Louie, 
Christine Waters, Zack Moore, Katrina Sleeman, 
Margaret Okomo-Adhiambo, Steven A. Marshall, 
Kirsten St. George, Chao-Yang Pan, Jennifer M. 
LaPlante, Alexander Klimov, and Alicia M. Fry
During April 2009–June 2010, thirty-seven (0.5%) of 
6,740 pandemic (H1N1) 2009 viruses submitted to a US 
surveillance system were oseltamivir resistant. Most pa-
tients with oseltamivir-resistant infections were severely im-
munocompromised (76%) and had received oseltamivir be-
fore specimen collection (89%). No evidence was found for 
community circulation of resistant viruses; only 4 (unlinked) 
patients had no oseltamivir exposure.
D
uring April, 2009–June, 2010 the United States had en-
hanced surveillance for oseltamivir resistance among 
pandemic inﬂ  uenza A (H1N1) 2009 viruses. We describe 
characteristics of patients infected with oseltamivir-resistant 
and oseltamivir-susceptible pandemic (H1N1) 2009 virus.
The Study 
During April 2009–June 2010, the Centers for Disease 
Control and Prevention (CDC) requested state public health 
laboratories to submit specimens for antiviral susceptibil-
ity testing by 2 routes. In the ﬁ  rst route, the ﬁ  rst 5 inﬂ  uenza 
specimens of any type or subtype collected every 2 weeks 
from each laboratory underwent virus isolation for compre-
hensive antiviral testing, including testing by neuraminidase 
inhibition (NI) assay, sequencing viruses with elevated 50% 
inhibitory concentration (IC50) values, and pyrosequencing 
for adamantine resistance–conferring M2 mutations. In the 
second route, the ﬁ  rst 5 additional clinical specimens from 
pandemic (H1N1) 2009 virus–infected patients that were 
collected each week by these laboratories were submitted 
and screened for the oseltamivir-resistant conferring neur-
aminidase H275Y mutation by using pyrosequencing. Pa-
tients with oseltamivir-resistant pandemic (H1N1) 2009 in-
fection had demographic and clinical information collected 
by using a standard form.
Oseltamivir resistance was determined by either NI or 
pyrosequencing for the H275Y mutation. NI was performed 
on virus isolates with a chemiluminescent substrate; viruses 
with elevated IC50 values for oseltamivir were identiﬁ  ed as 
resistant, based on previously set criteria (1,2). All oseltami-
vir-resistant viruses had H275Yconﬁ  rmed by pyrosequenc-
ing (1). Original clinical specimens collected from surveil-
lance were screened by pyrosequencing for H275Y, without 
NI. NI testing was performed at CDC, and pyrosequencing 
for H275Y was performed at CDC and state laboratories 
in Wisconsin, New York, and California. All oseltamivir-
resistant viruses referenced here were reported on FluView 
(3). Four patients, identiﬁ  ed in June and August 2009, were 
reported previously (4,5).
A comparison group of hospitalized patients infected 
with oseltamivir-susceptible pandemic (H1N1) 2009 was 
identiﬁ  ed from the Inﬂ  uenza Hospitalization Network (Flu-
Surv-NET). FluSurv-NET includes 10 states that participate 
in the Emerging Infections Program, a population-based 
surveillance for hospitalized patients with inﬂ  uenza infec-
tion (California, Colorado, Connecticut, Georgia, Maryland, 
Minnesota, New Mexico, New York, Oregon, Tennessee), 
plus 6 states (Iowa, Idaho, Michigan, North Dakota, Okla-
homa, South Dakota) added in response to the 2009 pan-
demic, as previously described (3,6). The counties within 
FluSurv-NET represent 26 million persons (8.5% of the 
US population) (6). The 16 states participating in FluSurv-
NET collected demographic and clinical information for all 
hospitalized patients with laboratory-conﬁ  rmed  inﬂ  uenza 
infection within their catchment counties (6). We identiﬁ  ed 
patients hospitalized in FluSurv-NET who had specimens 
submitted to national antiviral resistance surveillance by us-
ing Link Plus software to link antiviral resistance surveil-
lance and FluSurv-NET data by patient county of residence, 
age, and sex and specimen collection date.
We considered identical matches on all 4 variables as 
a high probability match, e.g., a patient from FluSurv-NET 
who had a pandemic (H1N1) 2009 virus specimen submitted 
to national antiviral resistance surveillance who had an osel-
tamivir-susceptible pandemic (H1N1) 2009 virus infection. 
We validated our linking methods with Oregon data (n = 41); 
all 4 patients identiﬁ  ed as high probability matches were true 
matches. For validation purposes, we identiﬁ  ed 4 specimens 
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men collection date up to 7 days, e.g., moderate probabil-
ity matches; 1 patient was hospitalized, 2 were outpatients, 
and 1 specimen was from a medical examiner (patient not 
hospitalized). The Oregon surveillance specimens that were 
neither high nor moderate probability matches were surveil-
lance specimens from outpatients and cluster investigations 
(M. Vandermeer, pers. comm.).
Overall, 6,740 virus isolates and specimens were sub-
mitted to surveillance systems; 37 (0.5%) viruses were os-
eltamivir resistant (3); 18 were identiﬁ  ed by NI, contained 
the H275Y mutation, and were susceptible to zanamivir and 
resistant to adamantanes; the 19 remaining viruses were de-
tected by pyrosequencing for H275Y. Oseltamivir-suscepti-
ble viruses exhibited IC50 values ranging from 0.05 to 1.44 
nmol/L. Oseltamivir-resistant viruses exhibited a median 
IC50 value of 80.08 nmol/L (range 6.24–116.48 nmol/L).
Most patients infected with oseltamivir-resistant pan-
demic (H1N1) 2009 viruses were hospitalized (81%), had 
a severe immunocompromising condition (76%), and had 
been exposed to oseltamivir before collection of the speci-
men tested for antiviral resistance (89%) (Table); 9 (30%) 
had received oseltamivir as chemoprophylaxis, and 21 
(70%) had received oseltamivir as treatment. Four patients 
with oseltamivir-resistant pandemic (H1N1) 2009 virus in-
fection had no documented exposure to oseltamivir before 
collection of the specimen for testing, including exposure 
to family members receiving oseltamivir. No epidemiologic 
links were found between the 4 patients.
Among the 28 patients infected with oseltamivir-
resistant pandemic (H1N1) 2009 virus, with a severe im-
munocompromising condition and a complete case form, 
24 (86%) had a malignancy reported, 23 had a hemato-
logic malignancy and were receiving chemo- or immuno-
suppressive therapy at the time of their infection, and 10 
(38%) were recipients of a hematopoietic stem cell trans-
plant (SCT). One patient had AIDS and a lymphoma of the 
central nervous system. Among the 3 immunosuppressed 
patients without a malignancy, 2 were recipients of solid 
organ (renal) transplants, and another had received SCT <6 
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Table. Characteristics of patients infected with oseltamivir-resistant and -susceptible pandemic (H1N1) 2009 viruses from national
influenza antiviral resistance surveillance and enhanced hospital influenza surveillance, April 2009–June 2010*† 
Characteristic
Oseltamivir-resistant infections Oseltamivir-susceptible infections





states,‡ n = 17
National surveillance 
cases from FluSurv-
NET counties, n = 401 
National surveillance 
cases matched in 
FluSurv-NET, n = 65
Median age, y (range)  18 (1–74)  21 (5–74)  22 (0–89)  31 (0–82) 
Female sex  18 (49)  6 (35)  177 (50)  38 (58) 
Hospitalized  30 (81)  16 (100)  65 (16)  65 (100) 
  ICU admission  13/30 (43)  7/12 (58)  – 14 (23) 
Deaths, all cause§ 7/31 (23)  2/12 (17)  – 3 (5) 
Oseltamivir exposure¶  31 (89)  16 (94)  – 6 (14) 
Underlying medical condition  33 (89)  17 (100)  – 49 (75) 
  Severe/Immunosuppression#  28 (76)  17 (100)  – 7 (11)** 
  Pregnancy  1 (2.7)  0 – 5 (7.7) 
  Asthma and CLD  10 (27)  2 (18)  – 21 (34) 
  CVD  8 (22)  4 (24)  – 5 (8) 
  Diabetes mellitus  5 (14)  2 (13)  – 12 (18) 
  Chronic kidney disease  4 (11)  3 (19)  – 5 (8) 
No underlying medical conditions  4 (11)  0 – 13 (21) 
Median time from oseltamivir initiation to 
specimen collection, d (range) 
11 (2–37)  14 (3–37)  – 1.5 (1–4)†† 
*Values are no. (%) except as indicated. FluSurv-NET, Influenza Hospitalization Network; ICU, intensive care unit; CLD, chronic lung disease; CVD, 
cardiovascular disease, excluding hypertension; –, not applicable. 
†Missing data were excluded from analysis; denominators are included where they varied from cohort size. 
‡Of the 16 oseltamivir-resistant cases from states participating in FluSurv-NET, 5 had county information and were from FluSurv-NET counties. None 
were high probability matches to a FluSurv-NET hospitalized patient and none were from Oregon. FluSurv-NET captured only 1 hospitalization for each 
patient infected with pandemic (H1N1) 2009 virus during the year. Repeat hospitalizations were not recorded, although many sites noted repeat 
hospitalizations for patients with immunosuppressive conditions (L. Kamimoto, pers. comm.).  
§Among oseltamivir-resistant cases, 4 deaths were reported to national surveillance as directly caused by influenza. Cause of death was not recorded for 
patients infected with oseltamivir-susceptible pandemic (H1N1) 2009 virus.  
¶Patients with oseltamivir exposure received oseltamivir, either as chemoprophylaxis or treatment, before the collection date of the pandemic (H1N1) 
2009 virus specimen tested for antiviral resistance.  
#For patients with oseltamivir-resistant pandemic (H1N1) 2009, severe immunosuppression was defined as any of the following: receiving treatment for 
any cancer within 6 months before onset of influenza illness, currently receiving immunosuppressive medication, including systemic corticosteroids, as 
part of prevention strategies for transplant (bone marrow or solid organ) rejection, or for management of pulmonary or autoimmune conditions, or having a 
diagnosis of AIDS, not just HIV infection. For patients within FluSurv-NET, we included any patient with a medical record of the syndromes above or if 
immunosuppressed or immunosuppression was recorded in the medical chart.  
**Among the 7 hospitalized patients from FluSurv-NET with oseltamivir-susceptible pandemic (H1N1) 2009 and an immunosuppressive condition, 3 (43%) 
were receiving chronic systemic corticosteroids; 1 for systemic lupus erythematosus and the other 2 for unknown reasons. The immunosuppressive 
condition was not known for 4 patients, but immunosuppression was recorded from the medical record. 
††n = 6. Oseltamivir-Resistant Pandemic (H1N1) 2009
months before inﬂ  uenza illness (reason for SCT could not 
be conﬁ  rmed).
Among 1,982 national surveillance oseltamivir-sus-
ceptible specimens from the 16 FluSurv-NET states, 1,607 
(81%) had county information; among these, 401 (25%) 
specimens were from FluSurv-NET counties, and 65 pa-
tients from FluSurv-NET were high probability matches to 
patients identiﬁ  ed in antiviral resistance surveillance data 
(Table). Compared with patients with oseltamivir-resistant 
pandemic (H1N1) 2009 infections identiﬁ  ed in national sur-
veillance, few (11%) FluSurv-NET patients with an osel-
tamivir-susceptible pandemic (H1N1) 2009 virus infection 
had severely immunosuppressive conditions, and few (14%) 
had oseltamivir exposure before collection of the specimen 
for testing, none were reported to have received oseltamivir 
as chemoprophylaxis. Among all 8,740 FluSurv-NET hos-
pitalized patients with pandemic (H1N1) 2009 during this 
period, 10% had an immunosuppressive condition. Patients 
with oseltamivir-resistant infections had specimens for test-
ing collected a median of 11 (range 2–37) days after oselta-
mivir initiation, and results may reﬂ  ect testing due to clinical 
suspicion of resistance. Among the 6 FluSurv-NET patients 
with specimens collected after oseltamivir was begun, the 
median time between oseltamivir initiation and specimen 
collection was shorter.
Conclusions
Infections with oseltamivir-resistant pandemic (H1N1) 
2009 viruses were rare in the United States during April 
2009–June 2010. Few patients had no oseltamivir exposure 
before resistant virus was detected, and none had epidemio-
logic links to another patient. Thus, evidence for community 
transmission of oseltamivir-resistant pandemic (H1N1) 2009 
viruses was rare (7). Patients with severe immunocompro-
mising conditions with prior exposure to oseltamivir were 
most likely to have an oseltamivir-resistant infection. Infec-
tions were most frequently reported in patients with hema-
tologic cancers who were undergoing immunosuppressive 
treatment, chemotherapy, or SCT. Other studies have also 
reported a high frequency of patients with hematologic ma-
lignancies or SCT and oseltamivir exposure among patients 
with oseltamivir-resistant pandemic (H1N1) 2009 virus in-
fections (8,9). Oseltamivir resistance should be considered 
among patients with severe immunocompromising condi-
tions and pandemic (H1N1) 2009 in the setting of oseltami-
vir treatment or chemoprophylaxis failure.
Although the number of patients with oseltamivir-resis-
tant pandemic (H1N1) 2009 virus infections was small in the 
United States during this period, this is the largest case series 
published and conﬁ  rms ﬁ  ndings from reports with smaller 
samples (8–10). Although all patients in our comparison 
group of patients with oseltamivir-susceptible pandemic 
(H1N1) 2009 were hospitalized, most patients in the oselta-
mivir-resistant group were also hospitalized. Finally, we do 
not have a comparison group of patients with immunocom-
promising conditions and oseltamivir-susceptible pandemic 
(H1N1) 2009 virus infections; thus, risk factors for infection 
with oseltamivir-resistant infection among patients with im-
munocompromising conditions cannot be determined. The 
ﬁ  nding of oseltamivir-resistant pandemic (H1N1) 2009 vi-
ruses associated with oseltamivir treatment highlights the 
need for new antiviral agents and new treatment strategies.
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